Institut Català de la Salut
[García-Muñoz E] Banc de Sang i Teixits, 08005 Barcelona, Spain. [Vives J] Banc de Sang i Teixits, 08005 Barcelona, Spain. Grup d'Enginyeria de Teixits Musculoesquelètics, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-02-25T13:50:52Z
2022-02-25T13:50:52Z
2021-06
Teixit adipós; Medul·la òssia; Cèl·lules estromals mesenquimals multipotents
Tejido adiposo; Médula ósea; Células estromales mesenquimales multipotentes
Adipose tissue; Bone marrow; Multipotent mesenchymal stromal cells
Multipotent mesenchymal stromal cells (MSCs) are currently the most extensively studied type of adult stem cells in advanced stages of development in the field of regenerative medicine. The biological properties of MSCs have generated great hope for their therapeutic use in degenerative and autoimmune conditions that, at present, lack effective treatment options. Over the last decades, MSCs have been typically obtained from adult bone marrow, but the extraction process is highly invasive and the quality and numbers of isolated cells is drastically influenced by patient age, medication and associated comorbidities. Therefore, there is currently an open discussion on the convenience of allogeneic over autologous treatments, despite potential disadvantages such as rejection by the host. This shift to the allogeneic setting entails the need for high production of MSCs to ensure availability of sufficient cell numbers for transplantation, and therefore making the search for alternative tissue sources of highly proliferative MSC cultures with low levels of senescence occurrence, which is one of the greatest current challenges in the scale up of therapeutic cell bioprocessing. Herein we (i) present the main isolation protocols of MSCs from bone marrow, adipose tissue and Wharton’s jelly of the umbilical cord; and (ii) compare their qualities from a bioprocess standpoint, addressing both quality and regulatory aspects, in view of their anticipated clinical use.
This work has been developed in the context of the Spanish Cell Therapy Network (TerCel, expedient number: RD16/0011/0028) and project PI19/01788, which is funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF)—A way to build Europe.
Article
Published version
English
Sistema nerviós - Degeneració - Tractament; Cèl·lules mare mesenquimàtiques - Ús terapèutic; DISEASES::Nervous System Diseases::Neurodegenerative Diseases; Other subheadings::Other subheadings::/therapy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Cell- and Tissue-Based Therapy::Cell Transplantation::Stem Cell Transplantation::Mesenchymal Stem Cell Transplantation; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades neurodegenerativas; Otros calificadores::Otros calificadores::/terapia; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::tratamientos basados en células y tejidos::trasplante de células::trasplante de células madre::trasplante de células madre mesenquimatosas
Springer
Cytotechnology;73
https://doi.org/10.1007/s10616-021-00474-3
info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F01788
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]